heterogeneous nuclear ribonucleoprotein A1 like 2Genealiases: []
Q-omics provides the consensus-scored HNRNPA1L2 profile across patient tissues and cancer cell-line models. HNRNPA1L2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HNRNPA1L2 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, HNRNPA1L2 RNA expression shows 19,996 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where HNRNPA1L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPA1L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPA1L2 survival associations across molecular data types. HNRNPA1L2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPA1L2 RNA expression–survival associations across cancer types. High HNRNPA1L2 expression shows unfavorable associations in ACC, KICH and COAD, but favorable associations in BRCA, HNSC and THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HNRNPA1L2 RNA expression.
This table summarizes HNRNPA1L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for HNRNPA1L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPA1L2 shows lower tumor expression in KICH, UCEC and THCA and higher tumor expression in COAD, HNSC and CHOL. The COAD box plot shows higher HNRNPA1L2 RNA expression in tumor versus normal tissue (log2 FC = +0.728, t-test p < 0.001).
This table shows molecular features associated with HNRNPA1L2 in patient tissues and cancer cell lines. In patient samples, HNRNPA1L2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HNRNPA1L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
